Delivery Order SPE2DB22D2206-SPE2DB25FJL68
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,032.63 to AmerisourceBergen Drug Corp for Butalbital-Aspirin-Caffeine 90-count tablets, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement issued on August 4, 2025, with performance to be completed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is a child contract under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,010.60 to AmerisourceBergen Drug Corp for Butalbital-Acetaminophen-Caffeine 50-325-40mg tablets (100 count) on July 29, 2025, with completion scheduled for July 30, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Butalbital-Acetaminophen-Caffeine 50-325-40 mg tablets in quantities of 100 units, with a contract ceiling value of $1,228.50. This delivery order represents a firm fixed-price transaction with no set-aside designation, indicating competitive award. The contract is classified as a child action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $2,538.79 to AmerisourceBergen Drug Corp for the supply of Butalbital-Acetaminophen-Caffeine 50-300-40mg tablets in a quantity of 100 units. This non-competitive, firm fixed-price delivery order was awarded on August 12, 2025, with an ultimate completion date of August 13, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This award...
- The Defense Logistics Agency awarded a $1,258.58 delivery order to AmerisourceBergen Drug Corp for Butalbital-Acetaminophen-Caffeine 50-325-40 mg tablets (500 count) on July 31, 2025, with completion expected by August 1, 2025. This firm fixed price, competitively awarded delivery order represents a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,218.87 firm-fixed-price delivery order, awarded on February 11, 2025, is for BUTALBITAL-ASPIRIN-CAFFEINE CP 100S, a pharmaceutical product, with a completion date of February 12, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,797.80 firm fixed-price contract is for the delivery of butalbital-aspirin-caffeine medication. The contract has an ultimate completion date of January 9, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for...
- This is a federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,342.71, is for the delivery of 4,565,468,599 units of the pharmaceutical product BUTALBITAL-ASPIRIN-CAFFEINE CP 90S. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 with the DLA Troop Support Medical, which enables the agency to efficiently procure a...
- The Defense Logistics Agency awarded a $25,050 firm fixed-price delivery order to Amerisourcebergen Drug Corporation for pharmaceutical products. Under the contract, Amerisourcebergen will provide 4562018550 BUTALB-ACETAMIN-CAFF 50-325-40 100S, described as acetaminophen, butalbital, and caffeine tablets, to be delivered to a facility in Conshohocken, Pennsylvania. The single order is for a one-day period of performance from August 31, 2023 to September 1, 2023. As the DLA supports the...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $1,176.38 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide BUTALB-ACETAMIN-CAFF 50-325-40 100S medical products. This contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for supplying a comprehensive range of pharmaceutical products and medical supplies to...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJL68Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,516.31 to AmerisourceBergen Drug Corp for Butalbital-Aspirin-Caffeine tablets (90-count) on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and will be performed at the company's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical vendor, serves as a prime contractor supporting military and veteran healthcare systems through the DLA's medical supply chain. This delivery order represents a small-value transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999.00 and extends through December 2026. The parent IDC functions as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The company continues to serve as a key vendor under DLA's Pharmaceutical Prime Vendor Global Program, which is structured to involve multiple regional contractors for enhanced supply chain flexibility and resilience.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 8/18/25 |